The First Hospital of Jilin University
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- -
- Established
- 1920-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.bethune-jilin.cn
Clinical Trials
138
Active:7
Completed:34
Trial Phases
6 Phases
Early Phase 1:2
Phase 1:8
Phase 2:22
+3 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (84 trials with phase data)• Click on a phase to view related trials
Not Applicable
43 (51.2%)Phase 2
22 (26.2%)Phase 1
8 (9.5%)Phase 4
8 (9.5%)Early Phase 1
2 (2.4%)Phase 3
1 (1.2%)Effect of Goal-Oriented Albumin Infusion on Postoperative Complication Management in Gastric Cancer Surgery
Not Applicable
Recruiting
- Conditions
- Postoperative HypoalbuminemiaPostoperative ComplicationsGastric Cancer
- Interventions
- Drug: Human Serum Albumin Infusion for LAT GroupDrug: Human Serum Albumin Infusion for HAT Group
- First Posted Date
- 2025-08-13
- Last Posted Date
- 2025-08-13
- Lead Sponsor
- The First Hospital of Jilin University
- Target Recruit Count
- 112
- Registration Number
- NCT07119463
- Locations
- 🇨🇳
First Hospital of Jilin University, Changchun, Jilin, China
Nefecon and Ambrisentan in IgA Nephropathy
Phase 4
Not yet recruiting
- Conditions
- IgA NephropathyChronic Kidney DiseaseProteinuria
- Interventions
- Drug: "Nefecon®","Ambrisentan"
- First Posted Date
- 2025-06-22
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- The First Hospital of Jilin University
- Target Recruit Count
- 129
- Registration Number
- NCT07030894
Phase II Trial of Zanubrutinib, Obinutuzumab, Bendamustine (ZGB) as First-Line Therapy for Chronic Lymphocytic Leukemia: A Single-Center Study
Phase 2
Not yet recruiting
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2025-06-04
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- The First Hospital of Jilin University
- Target Recruit Count
- 30
- Registration Number
- NCT07003464
- Locations
- 🇨🇳
The First Hospital of Jilin University, Changchun, Jilin, China
The Impact of Nafamostat Mesylate on the Prognosis of Patients With Sepsis-Induced Coagulopathy Undergoing Hemofiltration
Not Applicable
Not yet recruiting
- Conditions
- Sepsis-induced Coagulopathy (SIC)
- Interventions
- First Posted Date
- 2025-05-29
- Last Posted Date
- 2025-05-29
- Lead Sponsor
- The First Hospital of Jilin University
- Target Recruit Count
- 282
- Registration Number
- NCT06994312
Application of Transcriptome Sequencing Combined With Family-Based Whole Genome Sequencing in Improving Precise Diagnosis of Critically Ill Newborns in Northeast China
Not yet recruiting
- Conditions
- Necrotizing Enterocolitis
- First Posted Date
- 2025-05-25
- Last Posted Date
- 2025-05-25
- Lead Sponsor
- The First Hospital of Jilin University
- Target Recruit Count
- 1000
- Registration Number
- NCT06990334
- Prev
- 1
- 2
- 3
- 4
- 5
- 28
- Next
News
No news found